Pharmaceutical News

RSS

Study clarifies conflicting reports for clot aspiration and abciximab administration

The anti-platelet drug abciximab, delivered directly to lesions caused by a heart attack, significantly decreased damage to the heart muscle in high-risk patients while clot aspiration showed no impact, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session.

From Medtronic 27 Mar 2012

FDA issues Complete Response letter to MAP's NDA for LEVADEX

MAP Pharmaceuticals, Inc. today announced that the United States Food and Drug Administration (FDA) has issued a Complete Response letter to its New Drug Application (NDA) for LEVADEX (dihydroergotamine) inhalation aerosol.

27 Mar 2012

Viewpoints: Law on generic drugs is 'outrageous denial' of patients' rights; Could Romney be the best spokesman against federal law?

Dozens of suits against drug companies have been dismissed in federal and state courts because of a decision by the Supreme Court last year that makes it virtually impossible to sue generic manufacturers for failing to provide adequate warning of a prescription drug's dangers. This outrageous denial of a patient's right to recover fair damages makes it imperative that Congress or the Food and Drug Administration fashion a remedy.

27 Mar 2012

1 in 5 Australians have taken an expired medicine

NPS is urging all Australians to clean out their medicine cabinets today as part of national Be Medicinewise Week 2012. New research from NPS found around 1 in 5 people reported ever having taken an expired medicine.

26 Mar 2012

USANA Health Sciences expands into French and Belgium markets

USANA Health Sciences, Inc., a global nutritional supplements company, today announced the official opening of its France and Belgium markets. Bringing the company's international expansion to 18 countries worldwide, USANA's newest office will reside on the Champs-Elysees in Paris and will initially offer seven nutritional supplements and eight skin-care products.

26 Mar 2012

EMA accepts Arena's lorcaserin MAA for weight control

Arena Pharmaceuticals, Inc. announced today that the European Medicines Agency (EMA) has accepted the filing of a Marketing Authorization Application (MAA) for lorcaserin, an investigational drug candidate intended for weight control, including weight loss and maintenance of weight loss, in patients who are obese (BMI >30) or patients who are overweight (BMI >27) and have at least one weight-related co-morbid condition.

26 Mar 2012

FDA approves Teva's QNASL nasal aerosol corticosteroid

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has approved QNASL Nasal Aerosol, a new, "dry" nasal aerosol corticosteroid that treats seasonal nasal and year-round nasal allergy symptoms in adults and adolescents 12 years of age and older.

26 Mar 2012

AstraZeneca's lawsuit against FDA dismissed without prejudice

AstraZeneca today announced that on March 23, 2012 the US District Court for the District of Columbia issued an opinion and order in AstraZeneca's lawsuit against the US Food and Drug Administration regarding final marketing approval of generic quetiapine. The Court denied the Company's request for a preliminary injunction and dismissed the lawsuit without prejudice.

26 Mar 2012

Hypertension treatment fails to improve in the former Soviet Union

New research has found that treatment of hypertension has failed to improve in the last decade in the countries of the former Soviet Union. Hypertension, or high blood pressure, is one of the leading causes of avoidable deaths in the former Soviet Union.

26 Mar 2012

TOLMAR, Impax Labs partner for alternative dosage form products

Impax Laboratories, Inc. and TOLMAR, Inc. today announced that they will collaborate on a multiproduct agreement for the development, supply and distribution of alternative dosage form products.

26 Mar 2012

OSI Systems receives FDA clearance for Arkon anesthesia delivery system

OSI Systems, Inc., a vertically-integrated provider of specialized electronic products for critical applications in the Security and Healthcare industries, today announced that its Healthcare division, Spacelabs Healthcare, received clearance under Section 510(k) from the U.S. Food and Drug Administration to market the Arkon high-performance anesthesia delivery system.

26 Mar 2012

Rifaximin and lubiprostone offer best options for patients with IBS

Cedars-Sinai researchers have determined that two prevalent drug therapies - rifaximin and lubiprostone - offer some of the best options for treating irritable bowel syndrome, a widespread disorder that affects up to one in five Americans.

26 Mar 2012

USPTO issues patent to Inovio's SynCon H1N1 influenza vaccine

Inovio Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office granted U.S. Patent No. 8,133,723, covering Inovio's SynCon universal vaccine related to H1N1 influenza.

26 Mar 2012

Bacteriophages can tackle drug-resistant bacterial infections

Viruses that can target and destroy bacteria have the potential to be an effective strategy for tackling hard-to-treat bacterial infections. The development of such novel therapies is being accelerated in response to growing antibiotic resistance, says Dr David Harper at the Society for General Microbiology's Spring Conference in Dublin.

26 Mar 2012

Obese or overweight women may have increased risk of breast cancer recurrence

Women who are overweight or obese when they are diagnosed with breast cancer are at higher risk of cancer recurrence or related death than are leaner women, according to a new study to be presented to the 8th European Breast Cancer Conference.

26 Mar 2012

Metformin can have protective effects on the heart

The widely used diabetes medicine metformin can have protective effects on the heart, reveals a new study conducted at the Sahlgrenska Academy, at the University of Gothenburg, Sweden.

26 Mar 2012

FDA Advisory Committee to review Repligen's SecreFlo NDA on May 31

Repligen Corporation today announced that the U.S. Food and Drug Administration's Gastrointestinal Drugs Advisory Committee will meet on May 31, 2012 to discuss the Company's New Drug Application (NDA) for SecreFlo for the improved detection of pancreatic duct abnormalities in combination with magnetic resonance imaging (MRI) in patients with pancreatitis.

26 Mar 2012

Nerve pain patients in Wales gain access to first of a kind treatment which can provide lasting pain relief

For the first time NHS patients in Wales with peripheral nerve pain (known as peripheral neuropathic pain) can be treated with a patch containing capsaicin, which can provide at least 12 weeks pain relief following a single 30- or 60-minute application.

25 Mar 2012

57% of Australians make mistakes with their medicines

New research from NPS has found that 57% of Australians report they have made a mistake with their medicines in the past 12 months.

25 Mar 2012

Ibuprofen may be used effectively for altitude sickness: Study

Altitude sickness manifests by symptoms including a headache, fatigue, dizziness and sometimes nausea and vomiting. In addition, patients most likely also feel like they are working harder to breathe, like they are constantly trying to catch their breath. It normally takes days to weeks to fully acclimate to a higher altitude. It affects between 25 percent and 40 percent of the population and can be debilitating.

25 Mar 2012